Medifast FY 2023: revenue $1.1B, down 33%; diluted EPS $9.10

Key figures from this report

These are the numbers Medifast reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$1.1B−33% from $1.6B in FY 202210-K income statement, on EDGAR
2. Net income$99.4M−31% from $143.6M in FY 202210-K income statement, on EDGAR
3. Diluted EPS$9.10−29% from $12.73 in FY 202210-K income statement, on EDGAR
4. Cash and cash equivalents$94.4M+8% from $87.7M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$147.7M−24% from $194.6M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables